Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Inclusion Criteria:

• Diagnosis of CHE for at least 6 months prior to screening. Diagnosis of chromic handeczema (CHE) as defined by hand eczema (HE) lasting > 3 months or ≥ 2 flares withinthe previous 12 months.

• Screening and baseline IGA-CHE 3 or 4.

• Baseline CHE-related Itch NRS ≥ 4.

• Have been treated with at least 1 prescription CHE therapy or if such therapy wasnot advisable or contraindicated.

• Willingness to avoid pregnancy or fathering children based on the criteria definedin the protocol.

Exclusion Criteria:

• Known triggers for CHE (allergic or irritant, such as those identified by previouspatch tests) cannot be avoided during the course of this study.

• Any serious illness or medical, physical, or psychiatric condition(s).

• Laboratory values outside of the protocol-defined criteria.

• Use of protocol-defined treatments within the indicated washout period beforebaseline.

• Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4weeks before baseline.

• Pregnant or lactating participants, or those considering pregnancy during the periodof their study participation.

Other protocol-defined Inclusion/Exclusion Criteria may apply.